Biotech fundraising boom continues with CureVac IPO

CureVac_Covid-19_Vaccine_ PA_575_375
By Aidan Gregory
14 Aug 2020

Germany’s CureVac has gone public on the Nasdaq, joining the army of biotech companies that have tapped the equity capital markets for cash during the pandemic, despite growing concern of a brewing dot-com style bubble.

CureVac sold 13.33m shares at $16 each, the top of the range, raising $213m. The company will be valued at $2.7bn when it starts trading in New York on Friday morning.

If the greenshoe is used, the size of the IPO could grow to $245m

Berenberg, Bank of ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial